Atrial Fibrillation
Conditions
Keywords
Left Atrial Appendage
Brief summary
aMAZE CAP is an extension to the current aMAZE Trial investigation (IDEG150107/NCT02517397/Protocol Appendix 16) in the form of a nested, non-randomized registry, to allow ongoing treatment of subjects and the collection of additional safety and effectiveness data at existing aMAZE investigational sites.
Detailed description
For consistency, aMAZE CAP primary and secondary safety and efficacy endpoints, eligibility criteria and follow up visit assessments remain unchanged from the current aMAZE Trial investigation (NCT02517397).
Interventions
DEVICELARIAT + PVI
LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
Sponsors
AtriCure, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Documented diagnosis of symptomatic continuous persistent or longstanding persistent non-valvular atrial fibrillation * Failed at least one Class I or III Antiarrythmic drug (AAD) and therefore, eligible and intended for standard of care catheter ablation; * Life expectancy ≥ 1 year; * Willing and able to return to and comply with scheduled follow-up visits and tests; and * Willing and able to provide written informed consent
Exclusion criteria
* Prior procedure involving opening of the pericardium or entering the pericardial space (e.g., coronary artery bypass graft, heart transplantation, valve surgery) where adhesions are suspected; * Any prior epicardial ablation or any type of left-sided atrial ablation procedure; * LA diameter \> 6 cm as measured by computerized tomography and confirmed by the imaging core laboratory; * Documented embolic stroke, transient ischemic attach or suspected neurologic event within 3 months prior to the planned study intervention; * Currently exhibits New York Heart Association Class IV heart failure symptoms; * Documented history of right heart failure specifically when right ventricle exceeds the left ventricular size; * Documented history of myocardial infarction (MI) within 3 months prior to the planned study intervention; * Documented history of unstable angina within 3 months prior to the planned study intervention; * Documented history of cardiogenic shock, hemodynamic instability or any medical condition in which intra-aortic balloon pump (IABP) therapy is clinically indicated within 3 months prior to the planned study intervention; * Documented symptomatic carotid disease, defined as \> 70% stenosis or \> 50% stenosis with symptoms; * Diagnosed active local or systemic infection, septicemia or fever of unknown origin at tme of baseline screening; * Chronic renal insufficiency defined as eGFR \< 30 mL/min/1.73m2 within 3 months prior to planned study intervention; * End Stage Renal Disease (ESRD) or documented history of renal replacement / dialysis; * Current documented history of clinically significant liver disease which predisposes the subject to significant bleeding risk (clinically defined by the treating physician); * Any history of thoracic radiation with the exception of localized radiation treatment for breast cancer; * Current documented use of long-term treatment with oral corticoid steroids, not including use of inhaled steroids for respiratory diseases; * Active pericarditis; * Active endocarditis; * Any documented history or autoimmune disease associated with pericarditis; * Evidence of Pectus Excavatum (documented and clinically defined by the treating physician); * Untreated severe scoliosis (documented and clinically defined by treating physician); * Documented Left Ventricular Ejection Fraction (LVEF) \< 30% within 30 days prior to planned intervention; * Documented presence of implanted congenital defect closure devices, (e.g., atrial septal defect, patent foramen ovale or ventricular septal defect device); * Previously attempted occlusion of the left atrial appendage (by any surgical or percutaneous method); * Inability, or unwillingness or contraindication to undergo TEE or CTA imaging or 24-hour Holter monitoring; * Body Mass Index (BMI) \> 40; * Evidence of active Graves disease; * Current untreated hypothyroidism; * Any contraindication to suture, endovascular device, or other minimally invasive techniques including percutaneous, transseptal, and/or sub-xiphoid access; * Subject is pregnant or plans / desires to get pregnant within next 12 months; * Current enrollment in an investigation or study of an investigational device or investigational drug that would interfere with this study and the required follow up; * Mental impairment or other psychiatric conditions which may not allow patient to understand the nature, significance and scope of the study; * Any other criteria, medical illness or comorbidity which would make the subject unsuitable to participate in this study as determined by the clinical site Primary Investigator; Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from episodes of atrial fibrillation > 30 seconds at 12 months post index pulmonary vein isolation | 12 months following Pulmonary Vein Isolation catheter ablation procedure | Measured by 24-hour Holter Monitoring |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from any atrial fibrillation/atrial tachycardia/atrial flutter recurrence defined as any episode > 30 seconds with or without AAD | Following the 90 day blanking period through 12 months post-index pulmonary vein isolation | Measured by 24-hour Holter Monitoring |
| Composite endpoint of stroke of any cause and systemic embolism as adjudicated by the clinical events committee | 12 months following index pulmonary vein isolation | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| LARIAT Technical Success | Immediately post-LARIAT ligation (acute) and at 12 months following index pulmonary vein isolation | Successful placement of the LARIAT device pre-tied suture around the left atrial appendage to achieve left atrial appendage ligation defined as ≤1 ± 1mm diameter residual communication w/ left atrium, as assessed by transesophageal echocardiography |
Countries
United States
Outcome results
None listed